Research Article

Identification of Binding Mode of a Platinum (II) Complex, PtCl₂(DIP), and Calf Thymus DNA

Nahid Shahabadi, Soheila Kashanian, and Azadeh Fatahi

Department of Chemistry, Faculty of Science, Razi University, Kermanshah 74155, Iran

Correspondence should be addressed to Nahid Shahabadi, nahidshahabadi@yahoo.com

Received 28 July 2011; Revised 17 August 2011; Accepted 23 August 2011

Academic Editor: Albrecht Messerschmidt

Copyright © 2011 Nahid Shahabadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The Pt(II) complex, $PtCl_2(DIP)$ (DIP = chelating dinitrogen ligand: 4,7-diphenyl-1,10-phenanthroline), was synthesized and characterized by elemental analysis (CHN) and ¹H NMR and UV-vis techniques. The binding of this complex to calf thymus DNA was investigated using various physicochemical methods such as spectrophotometric, circular dichroism, spectrofluorometric, melting temperature, and viscosimetric techniques. Upon addition of the complex, important changes were observed in the characteristic UV-Vis bands (hyperchromism) of calf thymus DNA (CT-DNA): increase in melting temperature, sharp increase in specific viscosity of DNA, and induced CD spectral changes. Also the fluorescence spectral characteristics and interaction of Pt complex with DNA have been studied. Pt bound to DNA showed a marked decrease in the fluorescence intensity. The results show that both the complex and the NR molecules can intercalate competitively into the DNA double-helix structure. The experimental results show that the mode of binding of the this complex to DNA is classical intercalation.

1. Introduction

The interaction of transition metal complexes with DNA has long been the subject of intense investigation in relation to the development of new reagents for biotechnology and medicine [1-3]. In these complexes, metal or ligands can be varied in an easily controlled way to facilitate the individual applications. There are several types of sites in the DNA molecule where binding of metal complexes can occur (i) between two base pairs (intercalation), (ii) in the minor groove, (iii) in the major groove, and (iv) on the outside of the helix [4]. The observation that neutral platinum coordination compounds inhibit division and cell growth has generated much interest in the potential value of inorganic drugs in the field of cancer chemotherapy [5-10]. Cisplatin has been shown to have potent antitumor activity and is nowadays routinely employed in the treatment of several cancers [11-21]. However, because of its severe side effects a need for new platinum complexes has arisen, and several new derivatives have been synthesized and tested against various tumor model systems, with the hope of discovering new drugs with improved properties [9].

In the most successful second-generation cisplatin analogs (i.e., carboplatin), the chloride ligands have been replaced by a carboxylate. This structural variation in carboplatin seems to be responsible for the reduced toxicity of this compound [18, 19, 22]. In this paper, the Pt(II) complex, PtCl₂(DIP) (DIP = chelating dinitrogen ligand: 4,7-diphenyl-1,10 phenanthroline) (Figure 1), was synthesized and characterized by spectroscopic (¹H,¹³C NMR) and elemental analysis techniques. Binding interactions of this complex with calf thymus (CT) DNA have been investigated by UV absorption spectrophotometry, circular dichroism spectropolarimetry, melting temperature, and viscosimetry methods.

2. Materials and Methods

2.1. Material. Commercially pure chemicals, such as 4,7diphenyl-1,10 phenanthroline (Merck), Neutral Red (Third Reagent Factory, Shanghai), Tris-HCl (Sigma Co., Madrid Spain), were used as purchased. Experiments were carried out in Tris-HCl buffer (10 mM, pH 7.2). Solution



FIGURE 1: Schematic structure of PtCl₂(DIP) (DIP = chelating dinitrogen ligand: 4,7-diphenyl-1,10 phenanthroline).

was prepared with distilled water. Highly polymerized calf thymus DNA (CT-DNA) was purchased from Sigma Co. $[PtCl_2(DMSO)_2]$ (DMSO = dimethyl sulfoxide) was prepared as already described [23].

The stock solution of DNA was prepared by dissolving of DNA in 10 mM of the Tris-HCl buffer at pH 7.2. A solution of CT-DNA gave a ratio of UV absorbance at 260 and 280 nm more than 1.8, indicating that DNA was sufficiently free from protein.

The DNA concentration (monomer units) of the stock solution was determined by UV spectrophotometery, in proerly diluted samples, using the molar absorption coefficient $6600 \text{ M}^{-1} \text{ cm}^{-1}$ at 260 nm [24]. The stock solution was stored at 4°C.

To study the platinum complex interaction with DNA, stock solutions were prepared by dissolving the complex in the Tris-HCl buffer used in this study to a final concentration of $0.5 \text{ mg} \cdot \text{mL}^{-1}$ and incubated for 24 h at 37°C after addition of DNA.

2.2. Synthesis of PtCl₂(DIP). The appropriate amount of diphenyl phenanthroline ligand (DIP) (1 mmol) in methanol (5 mL) was added dropwise to a stirred solution of [PtCl₂ (DMSO)] (1 mmol) in the same solvent (30 mL). After 12 h of stirring the light red solid was collected, washed with methanol and diethyl ether, and dried in air. Yeild 83%. Anal. *Calc.* for C₂₄H₁₆N₂Cl₂Pt: C, 48.0; H, 2.67; N, 4.67. Found: C, 48.5; H, 2.9; N, 4.5. ¹H NMR of the complex: $\delta = 8.54$ (d, 2 H atoms of phen ligand), $\delta = 8.06$ (d, 2H atoms of phen ligand), $\delta = 7.83$ (d, 2H atoms of phen ligand), $\delta = 7.28$ (m, 10 H atoms of phenyl groups). ¹H NMR of the DIP ligand: $\delta = 9.29$ (d, 2 H atoms of phen ligand), $\delta = 7.79$ (d, 2H atoms of phen ligand), $\delta = 7.57$ (d, 2H atoms of phen ligand), $\delta = 7.55$ (m, 10 H atoms of phenyl groups). In the ¹H NMR spectrum of $Pt(DIP)Cl_2$ the signals due to the various protons of 4,7-diphenyl-1,10 phenanthroline ligand are seen to be shifted with corresponding free ligand and suggesting complexation.

2.3. Methods. The complex obtained was characterized by elemental analysis, UV-Vis, and ¹H NMR spectroscopy. The

elemental analysis was performed using a Heraeus CHN elemental analysis. The ¹H NMR spectra were recorded with a Bruker Avance DPX 200 MHz (4.7 Tesla) spectrometer using CDCl₃ as solvent and sodium 3-(trimethylsilyl)tetradeuteriopropionate as internal standard.

Absorbance spectra were recorded using an hp spectrophotometer (Agilent 8453). Circular dichroism (CD) measurements were recorded on a JASCO (J-810) spectropolarimeter. Solutions of DNA and platinum, which were prepared as described previously, were scanned in 0.5 cm (1 mL) quartz cuvette. The spectra were recorded after incubation at 37°C for 24 h. For viscosity measurements, a viscosimeter (SCHOT AVS 450) which thermostated at 25°C by a constant temperature bath was used. Flow time was measured with a digital stopwatch; the mean values of three replicated measurements were used to evaluate the viscosity $\dot{\eta}$ of the samples. The data were reported as $(\eta/\eta^{\circ})^{1/3}$ versus 1/R that $R = [DNA]/[PtCl_2(DIP)]$ ratio [25], where η° is the viscosity of the DNA solution alone. For DNA melting studies, we used a Cary (UV 100 Bio) spectrophotometer equipped with a temperature controller (COMPLEX PTS 100 Bio) and the temperature of the cell holder was changed as: 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, and 90°C.

All fluorescence measurements were carried out with a JASCO spectrofluorometer (FP6200).

3. Results and Discussion

3.1. Electronic Spectra. Electronic absorption spectra are initially employed to study the binding of complexes to DNA. In the present study, the interaction of Pt (II) complex with CT-DNA has been monitored in aqueous solution. Aliquots of the DNA solution at a constant concentration equal to 5×10^{-5} incubated with Pt complex at r_i values of 0.1-0.7 in 10 mM Tris-HCl buffer, (pH 7.2) at 37°C. The r_i values were calculated from the following equation: $r_i = [\text{complex}]/[\text{DNA}]$. The UV band of DNA at about 260 nm was monitored at the absence and presence of different amounts of Pt (II) complex. "Hyperchromic" effect and "hypochromic" effect are the spectra features of DNA concerning its double-helical structure [26]. The spectral change process reflects the corresponding changes in DNA in its conformation and structures after the drug bound to DNA. Hypochromism results from the contraction of DNA in the helix axis, as well as from the change in conformation on DNA; in contrast, hyperchromism derives from damage to the DNA double-helix structure [27, 28]. In contrast, as shown in Figure 2, the absorption spectra of DNA increase with increasing complex concentration. This is a typical "hyperchromic" effect which suggests that the DNA doublehelix structure is damaged after the complex bound to DNA through intercalation mode.

3.2. Thermal Denaturation Experiments. The consequences of adduct formation on the stability of the double helix in CT-DNA were assayed by recording the DNA melting profiles. Thermal behavior of DNA in the presence of complexes can give insight into their conformational changes



FIGURE 2: Absorption spectra of (a) DNA $(5 \times 10^{-5} \text{ M})$ in the absence (strong line) and presence of increasing amounts of Pt complex: $r_i = [\text{Complex}]/[\text{DNA}] = 0.0, 0.1, 0.3, 0.5, 0.7.$



FIGURE 3: Melting curves of CT-DNA (5×10^{-5} M) in the absence and in the presence of Pt complex at various $r_i = [\text{Complex}]/[\text{DNA}]$ = 0.0, 0.1, 0.2, 0.4 in Tris-HCl (10 mM), pH = 7.2.

when temperature is raised and offer information about the interaction strength of complexes with DNA. The stabilization of CT-DNA through the hydrogen-bonding and electrostatic interactions of the noncovalent complexes was further assessed by measuring the melting temperature. We measured the changes in the absorbance at 260 nm as a function of temperature for calf thymus DNA in the absence and presence of complex. Our experiments were carried out for CT-DNA in the absence and presence of different amounts of platinum complex. The denaturation temperatures were increased for the ratio of complex to DNA ($r_i = 0, 0.1, 0.2$, and 0.4, resp.; Figure 3). The denaturation temperatures were increased as 67, 70, 75, and 84.5°C for the ratio of complex to DNA ($r_i = 0, 0.1, 0.2$ and 0.4, resp.). These results are due to the stabilization of the DNA helix in the presence of intercalative complex. This stabilizing action of complex is very similar to that of previously observed for daunomycin [29], cryptolepine [30] and Chlorobenzylidene [31]. This provides another support for the intercalation of complex into the DNA double helix.

3.3. Circular Dichroism. Circular dichroism (CD) spectroscopy is a very useful method to analyze the structure of optically active materials such as proteins and DNA; therefore, the CD technique was used to determine the DNA confor-



FIGURE 4: Circular dichroism spectra of CT-DNA (5 × 10⁻⁵ M) in Tris-HCl (10 mM), in the presence of increasing amounts of Pt complex at the following stoichiometric ratios: $r_i = [\text{complex}]/[\text{DNA}] = 0.0, 0.05, 0.15, 0.25.$

mational changes induced by complex pt. It should be noted that the titled platinum (II) complex is optically inactive and hence dose not exhibit any CD spectra. CD spectra were measured at various ratios of the complex to DNA. The observed CD spectrum of calf thymus DNA consists of a positive band at 275 nm due to base stacking and a negative band at 245 nm due to helicity, which is characteristic of DNA in right-handed B form, in the ultraviolet region [32]. The results of CD studies indicated that by increasing of [complex]/[DNA] ratio, clear changes occurred in the CD spectra of B-DNA (Figure 4). The intensities of negative band decreased (shifting to zero levels) along with a bathochromic effect (Red Shift) about 4.0 nm, while the positive bands increased significantly without any changes in their wavelength (Figure 4). Similar changes in CD spectra with various interpretations have been reported. For example, some investigators believed that this type of changes in the CD spectra may be reflected of a shift from a B-like DNA structure toward one with some contributions from an Alike conformation [33, 34], but this phenomenon could be due to groove binding that stabilizes the right-handed B form of DNA [35]. This enhancement of the CD band of DNA at 275 nm is due to distortions induced in the DNA structure [36]. We think the increasing of CD signal around 275 nm along with increasing of platinum complex is an important evidence for the intercalation of the complex with the base pairs, which concurs with the data reported by other researchers [37, 38] and also confirms our other evidences. In addition, red shift of the CD spectra at 245 nm suggests that there exists interaction between aromatic rings of the complex and base pairs of DNA [37]. Also, molar ellipticity values were calculated according to the formula [39]:

$$[\theta]_{\lambda} = \frac{100\theta_{(\lambda)}}{lC},\tag{1}$$

where $[\theta]_{\lambda}$ is the molar ellipticity value at a particular wavelength expressed in deg cm² dmol⁻¹, *C* the concentration in moles of nucleotide phosphate per liter, *l* the length of the cell in dm, and θ_{λ} is the observed rotation in degrees (°). The results are summarized in Table 1.

TABLE 1: Effects of Pt complex on the CD spectra of DNA, in tris HCL buffer.

$\theta_{245\mathrm{nm}}$	$ heta_{ m 275nm}$
-80444	55752
-81110	616084
-62994	78404
-62343	86919

3.4. Viscosity Measurements. As a means for further exploring the binding of the complex to DNA, viscosity measurements were carried out by varying the concentration of the added complex to DNA solution. The values of relative specific viscosity $(\eta/\eta_0)^{1/3}$ versus 1/R (R = [DNA]/[complex]) in the absence and in the presence of complex in tris HCL buffers, were plotted (Figure 5). Figure 5 shows that the specific viscosity of the DNA sample clearly increases with the addition of the complex. The viscosity studies provide a strong argument for intercalation [40]. It is known that the groove binder like Hoechst 33258 does not cause an increase in the axial length of the DNA and therefore did not alter the relative viscosity. In contrast, cisplatin which is known to kink DNA through covalent binding, shortening the axial length of the double helix, caused a decrease in the relative viscosity of the solution. Partial intercalators also reduce the axial length observed as a reduction in relative viscosity, whereas the classical organic intercalators such as ethidium bromide increased the axial length of the DNA and it becomes more rigid resulting in an increase in the relative viscosity [41]. Results confirm the sensitivity of viscosity measurements to the different modes of DNA binding. In this paper, it was observed that increasing the platinum complex concentration leaded to an increase of the DNA viscosity. Thus, we may deduce that the $[PtCl_2(DIP)]$ complex, certainly is a DNA intercalator. In essence, the length of the linear piece of B-form DNA is given by the thickness of the base pairs that are stacked along the helix axis in van der Waals contact with each other. Introducing another aromatic molecule into the stack therefore increases the length. So, we think the viscosity increase of the DNA caused by the addition of the complex can provide further support for the intercalative mode of binding. Since the interaction of this platinum (II) complex with DNA can make DNA longer, we would expect that the relative viscosity of DNA increases with a slope between 0 and 0.96 (a value measured for ethidium bromide [42]) if the intercalation of the Pt(II) complex was either only one interaction mode or much stronger than other interaction(s). But, in this study, the relative viscosity of DNA increase with a slope of 0.71 (Figure 5) and it is reasonably believed that may be other interaction(s) between DNA and the Pt(II) complex occurred and is reasonable for the decrease of the slope. These results clearly show that the importance of using several techniques to ascertain intercalation.

3.5. Fluorescence Studies. The excitation wavelength at 280 nm was used for the fluorescence measurements and the emission spectra were recorded between 300 and 500 nm.



FIGURE 5: Effect of increasing amounts of complex on the viscosity of CT-DNA (5×10^{-5} M) in Tris-HCl (10 mM).

The excitation and emission slits were both 10 nm, and the scan speed was 200 nm min^{-1} . Fluorescence titration experiments were performed by keeping the complex concentration constant and stoichiometrically varying the DNA concentration. Each spectrum was scanned for three times to acquire the final fluorescence emission spectra. Our results (Figure 6) show that in presence of excess of DNA the fluorescence intensity was completely quenched. This indicated that all fractions of the binding sites of the complex interacted with DNA. Stern-Volmer plots for DNA quenching were obtained by using the Stern-Volmer equation:

$$\frac{F_0}{F} = 1 + K_q[Q],$$
 (2)

where F_0 = fluorescence intensity of fluorophore in absence of quencher; F = fluorescence intensity of fluorophore in presence of quencher; K_q = Stern-Volmer constant; [Q] = quencher concentration. However, the Stern-Volmer plots for quenching of the fluorescence intensity by DNA deviate from linearity at quencher concentrations larger than $1.0 \times$ 10^{-5} M. In addition, by increasing the temperature, the fluorescence intensity of the complex increased whether there was DNA in the solution or not, and the K_q decreased with the temperature rising. These results indicate that the probable quenching mechanism of fluorescence by DNA is a static quenching procedure [43], that is, a complex was formed between the DNA base pairs and the complex. Because it was the static quenching, the quenching constant was considered as the formation constant of the complex and DNA [44, 45].

3.5.1. Thermodynamic Measurements. To obtain a detailed view of the interaction between the platinum complex and DNA, a powerful approach is to parse the free energy of the binding reaction into its component terms. The four classes of noncovalent interactions that can play a role in the binding



FIGURE 6: Effect of DNA on the fluorescence spectra of Pt complex $(8.34 \times 10^{-5} \text{ M})$ in Tris-HCl (10 mM) buffer. $r_i = [\text{DNA}]/[\text{Complex}] = 0.0, 0.2, 0.6, 0.8, 1, 1.2.$

of drug molecules to biomolecules are hydrogen bonds, van der Waals forces, electrostatic interactions, and hydrophobic bond interactions.

In the intercalation process, a planar aromatic chromophore is inserted between two adjacent base pairs in a DNA helix. Alternatively, in minor groove binding, an isohelical drug molecule binds in the minor groove of DNA without inducing significant structural changes in the DNA [46]. While the complex formed from intercalation is stabilized by hydrophobic interactions and van der Waals forces, the complex formed from minor groove binding is stabilized mainly by hydrophobic interactions [46].

Consequently, in this study, the formation constant for complex-DNA adduct formation is evaluated at four different temperatures (277, 27, 298, 310) allowing for the determination of thermodynamic parameters such as enthalpy (ΔH) and entropy (ΔS) by the Van't Hoff equation. Binding constant (K_f) values were obtained from experimental results at four different temperatures. The thermodynamic parameters ΔS and ΔH were calculated from these binding constants. Ross and coworkers [47] reported that when $\Delta H < 0$ or $\Delta H \approx 0$ and $\Delta S > 0$, the electrostatic force dominates the interaction; when $\Delta H < 0$ and $\Delta S < 0$, van der Waals interactions or hydrogen bonds dominate the reaction; and when $\Delta H > 0$ and $\Delta S > 0$, hydrophobic interactions dominate the binding process. The positive slope in the Van't Hoff plot indicates that the reaction of DNA with the complex is exothermic and enthalpy favored. The ΔH and ΔS values of the complex-DNA adduct were -64.12 kJ/mol and -127.74 J/mol, respectively. From the thermodynamic data, it is quite clear that while complex formation is enthalpy favored, it is also entropy disfavored. Formation of the complex therefore results in a more ordered state, possibly due to the freezing (fixing) of the motional freedom of both the complex and DNA molecules. In conclusion, entropy and enthalpy changes are confirmed the intercalation mode of binding.

In order to investigate the mode of Pt complex binding to DNA, Neutral Red (NR) has been employed in examination of the reaction, as NR presumably binds initially to DNA by intercalation. Neutral Red is a planar phenazine dye, and in general, is structurally similar to other planar dyes, for



FIGURE 7: Effect of Pt complex on fluorescence spectra of NR-DNA. cDNA = 7.74×10^{-5} M; cNR = 1.00×10^{-5} M; and c Pt complex = 0.00, 0.25, 0.5, 0.75, 1.00, and 2.00×10^{-5} M for curves 1–6, respectively.

example, those of the acridine, thiazine, and xanthene kind. In recent years, the interaction of the fluorescent NR dye with DNA has been demonstrated by spectrophotometric [48] and electrochemical [49] techniques. Compared with a common fluorimetric probe, ethidium bromide (EB) [50, 51], the NR dye offers lower toxicity, higher stability and convenience of use [52]. In addition, its solution remains stable for up to 2 years. fluorescent spectra collected from a solution of fixed [NR] and different [DNA] concentrations. Thus, NR can be used to probe the interaction of small molecules with DNA. With the addition of Pt complex to a solution of NR-DNA, some NR molecules were released into solution after an exchange with the Pt complex, and this resulted in fluorescence quenching (Figure 7). This supported the view that the complex intercalated into the DNA [53].

4. Conclusion

The new platinum (II) complex exhibits a high binding affinity for CT-DNA. Different instrumental methods were used to investigate the interaction mechanism. The results support the notion that the complex can bind to CT-DNA by intercalation. The absorption spectrum of the DNA shows a large degree of hyperchromism develops in the spectrum. Hyperchromism is usually characteristic of interactions between DNA and the complex and arises from the strong stacking interaction between the aromatic chromophore and the base pairs. The fluorescence studies showed an appreciable decrease in the emission upon addition of DNA. The positive slope in the Van't Hoff plot indicates that the reaction between the complex and DNA was enthalpyfavored ($\Delta H = -64.12 \text{ kJ/mol}$). CD results showed deep conformational changes in the CT-DNA double helix upon binding with the complex. The increase in the relative viscosity as well as melting temperature of CT-DNA in the presence of the complex shows that intercalation must be the predominant form of binding.

Acknowledgment

Financial support from the Razi University Research Center is gratefully acknowledged.

References

- C. Tu, X. Wu, Q. Liu, X. Wang, Q. Xu, and Z. Guo, "Crystal structure, DNA-binding ability and cytotoxic activity of platinum(II) 2,2'-dipyridylamine complexes," *Inorganica Chimica Acta*, vol. 357, no. 1, pp. 95–102, 2004.
- [2] S. R. Chowdhury, K. K. Mukherjea, and R. Bhattacharyya, "Biophysical and biochemical investigation on the binding of a manganese—cyanonitrosyl complex with DNA," *Transition Metal Chemistry*, vol. 30, no. 5, pp. 601–604, 2005.
- [3] Y.-M. Song, X.-L. Lu, M.-L. Yang, and X.-R. Zheng, "Study on the interaction of platinum(IV), gold(III) and silver(I) ions with DNA," *Transition Metal Chemistry*, vol. 30, pp. 499–502, 2005.
- [4] A. M. Pyle, J. P. Rehmann, R. Meshoyrer, C. V. Kumar, N. J. Turro, and J. K. Barton, "Mixed-ligand complexes of ruthenium(II): factors governing binding to DNA," *Journal of the American Chemical Society*, vol. 111, no. 8, pp. 3051–3058, 1989.
- [5] T. W. Hambley, "The influence of structure on the activity and toxicity of Pt anti-cancer drugs," *Coordination Chemistry Reviews*, vol. 166, pp. 181–223, 1997.
- [6] M. Green, M. Garner, and D. M. Orton, "Literature highlights-29—Cisplatin-the last five years," *Transition Metal Chemistry*, vol. 17, no. 2, pp. 164–176, 1992.
- [7] E. Wong and C. M. Giandornenico, "Current status of platinum-based antitumor drugs," *Chemical Reviews*, vol. 99, no. 9, pp. 2451–2466, 1999.
- [8] E. R. Jamieson and S. J. Lippard, "Structure, recognition, and processing of cisplatin-DNA adducts," *Chemical Reviews*, vol. 99, no. 9, pp. 2467–2498, 1999.
- [9] J. Reedijk, "Improved understanding in platinum antitumour chemistry," *Chemical Communications*, no. 7, pp. 801–806, 1996.
- [10] J. Reedijk, "Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?" *Chemical Reviews*, vol. 99, no. 9, pp. 2499–2510, 1999.
- [11] E. Lindauer and E. Holler, "Cellular distribution and cellular reactivity of platinum(II) complexes," *Biochemical Pharmacol*ogy, vol. 52, no. 1, pp. 7–14, 1996.
- [12] G. B. Onoa, G. Cervantes, V. Moreno, and M. J. Prieto, "Study of the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy," *Nucleic Acids Research*, vol. 26, no. 6, pp. 1473–1480, 1998.
- [13] C. Molenaar, J. M. Teuben, R. J. Heetebrij, H. J. Tanke, and J. Reedijk, "New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy," *Journal of Biological Inorganic Chemistry*, vol. 5, no. 5, pp. 655–665, 2000.
- [14] E. G. Talman, W. Brüning, J. Reedijk, A. L. Spek, and N. Veldman, "Crystal and molecular structures of asymmetric cis- and trans-platinum(II/IV) compounds and their reactions with DNA fragments," *Inorganic Chemistry*, vol. 36, no. 5, pp. 854–861, 1997.
- [15] P. M. Takahara, A. C. Rosenzweig, C. A. Frederick, and S. J. Lippard, "Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin," *Nature*, vol. 377, no. 6550, pp. 649–652, 1995.

- [16] H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger, and H. Schonenberger, "Synthesis and antitumor activity of platinum(II) complexes containing substituted ethylenediamine ligands," *European Journal of Medicinal Chemistry*, vol. 25, no. 1, pp. 35–44, 1990.
- [17] G. Faraglia, L. Sindellari, and S. Sitran, "Spectroscopic and thermal studies on platinum(II) iodide complexes with primary amines," *Thermochimica Acta*, vol. 115, pp. 229–239, 1987.
- [18] V. Cherchi, G. Faraglia, L. Sindellari et al., "Platinum(II) complexes with alkylamines characterization and in vitro cytostatic activity," in *Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*, M. Nicolini, Ed., Boston, Mass, USA, 1988.
- [19] S. Moradella, J. Lorenzob, A. Rovira et al., "Platinum complexes of diaminocarboxylic acids and their ethyl ester derivatives: the effect of the chelate ring size on antitumor activity and interactions with GMP and DNA," *Journal of Inorganic Biochemistry*, vol. 96, no. 4, pp. 493–502, 2003.
- [20] M. S. Robillard, M. Galanski, W. Zimmermann, B. K. Keppler, and J. Reedijk, "(Aminoethanol)dichloroplatinum(II) complexes: Influence of the hydroxyethyl moiety on 5'-GMP and DNA binding, intramolecular stability, the partition coefficient and anticancer activity," *Journal of Inorganic Biochemistry*, vol. 88, no. 3-4, pp. 254–259, 2002.
- [21] M. Meroueh, J. Kjellstrom, K. S. M. Martensson, S. K. C. Elmroth, and C. S. Chow, "Reactions of platinum (II) complexes with a DNA hairpin, d(CGCGTTGTTCGCG): structural characterization and kinetic studies," *Inorganica Chimica Acta*, vol. 297, no. 1-2, pp. 145–155, 2000.
- [22] D. Lebwohl and R. Canetta, "Clinical development of platinum complexes in cancer therapy: an historical perspective and an update," *European Journal of Cancer*, vol. 34, no. 10, pp. 1522–1534, 1998.
- [23] Y. N. Kukushkin, Y. E. Vyaz'menskii, L. I. Zorina, and Y. L. Pazukhina, "Complexes of palladium and platinum with dimethyl sulfoxide," *Russian Journal of Inorganic Chemistry*, vol. 13, pp. 835–838, 1968.
- [24] J. Sambrook, E. F. Fritsche, and T. Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1989.
- [25] R. Vijayalakshmi, M. Kanthimathi, V. Subramanian, and B. U. Nair, "Interaction of DNA with [Cr(Schiff base)(H₂O)₂]ClO₄," *Biochimica et Biophysica Acta*, vol. 1475, no. 2, pp. 157–162, 2000.
- [26] K. Akdi, R. A. Vilaplana, S. Kamah, and F. Gonzalez-Vilchez, "Effects of Tris and Hepes buffers on the interaction of palladium–diaminopropane complexes with DNA," *Journal of Inorganic Biochemistry*, vol. 99, pp. 1360–1368, 2005.
- [27] Q. Li, P. Yang, H. Wang, and G. Maolin, "Diorganotin(IV) antitumor agent. (C₂H₅)₂ SnCl₂ (phen)/nucleotides aqueous and solid-state coordination chemistry and its DNA binding studies," *Journal of Inorganic Biochemistry*, vol. 64, no. 3, pp. 181–195, 1996.
- [28] S. Shi, J. Liu, J. Li et al., "Synthesis, characterization and DNAbinding of novel chiral complexes Δ- and Λ-[Ru(bpy)₂L]₂+ (L = *o*-mopip and *p*-mopip)," *Journal of Inorganic Biochemistry*, vol. 100, no. 3, pp. 385–895, 2006.
- [29] J. B. Chaires, N. Dattagupta, and D. M. Crothers, "Equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid," *Biochemistry*, vol. 21, no. 17, pp. 3933–3940, 1982.
- [30] K. Bonjean, M. C. De Pauw-Gillet, M. P. Defresne et al., "The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16

melanoma cells," *Biochemistry*, vol. 37, no. 15, pp. 5136–5146, 1998.

- [31] W. Zhong, J. S. Yu, Y. Liang, K. Fan, and L. Lai, "Chlorobenzylidine-calf thymus DNA interaction II: Circular dichroism and nuclear magnetic resonance studies," *Spectrochimica Acta A*, vol. 60, no. 13, pp. 2985–2992, 2004.
- [32] S. Ramakrishnan and M. Palaniandavar, "Mixed-ligand copper(II) complexes of dipicolylamine and 10-phenanthrolines: the role of diimines in the interaction of the complexes with DNA," *Journal of Chemical Sciences*, vol. 117, no. 2, pp. 179– 186, 2005.
- [33] N. Poklar, D. S. Pilch, S. J. Lippard, E. A. Redding, S. U. Dunham, and K. J. Breslauer, "Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 15, pp. 7606–7611, 1996.
- [34] F. H. Li, G. H. Zhao, H. X. Wu et al., "Synthesis, characterization and biological activity of lanthanum(III) complexes containing 2-methylene-10-phenanthroline units bridged by aliphatic diamines," *Journal of Inorganic Biochemistry*, vol. 100, no. 1, pp. 36–43, 2006.
- [35] A. K. Patra, M. Nethaji, and A. R. Chakravarty, "Synthesis, crystal structure, DNA binding and photo-induced DNA cleavage activity of (S-methyl-l-cysteine)copper(II) complexes of heterocyclic bases," *Journal of Inorganic Biochemistry*, vol. 101, no. 2, pp. 233–244, 2007.
- [36] J. Kasparkova, O. Vrana, N. Farrell, and V. Brabec, "Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding," *Journal of Inorganic Biochemistry*, vol. 98, no. 10, pp. 1560–1569, 2004.
- [37] W. Zhong, J. S. Yu, Y. Liang, K. Fan, and L. Lai, "Chlorobenzylidine-calf thymus DNA interaction II: Circular dichroism and nuclear magnetic resonance studies," *Spectrochimica Acta A*, vol. 60, no. 13, pp. 2985–2992, 2004.
- [38] D. G. Dalgleish, G. Fey, and W. Kersten, "Circular dichroism studies of complexes of the antibiotics daunomycin, nogalamycin, chromomycin, and mithramycin with DNA," *Biopolymers*, vol. 13, no. 9, pp. 1757–1766, 1974.
- [39] G. D. Fasman, Circular Dichroism and Conformational Analysis of Biomolecules, Plenum Press, New York, NY, USA, 1996.
- [40] L. P. G. Wakelin, G. J. Atwell, G. W. Rewcastle, and W. A. Denny, "Relationships between DNA-binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumor agents," *Journal of Medicinal Chemistry*, vol. 30, pp. 855–861, 1987.
- [41] N. Shahabadi, S. Kashanian, and M. Purfoulad, "DNA interaction studies of a platinum(II) complex, PtCl₂(NN) (NN = 4,7dimethyl-10-phenanthroline), using different instrumental methods," *Spectrochimica Acta A*, vol. 72, no. 4, pp. 757–761, 2009.
- [42] F. H. Li, G. H. Zhao, H. X. Wu et al., "Synthesis, characterization and biological activity of lanthanum(III) complexes containing 2-methylene–1,10-phenanthroline units bridged by aliphatic diamines," *Journal of Inorganic Biochemistry*, vol. 100, no. 1, Article ID 10.1016/j.jinorgbio.2005.09.012, pp. 36– 43, 2006.
- [43] P. Yang, Introduction of Bioinorganic Chemistry, Xi'An Jiao-Tong University, Xi'An, China, 1991.
- [44] Y. Cao and H. Xi-wen, "Studies of interaction between Safranine T and double helix DNA by spectral methods," *Spectrochimica Acta Part A*, vol. 54, pp. 883–892, 1998.
- [45] G.-Z. Chen, X.-Z. Huang, J.-G. Xu, Z.-Z. Zheng, and Z.-B. Wang, *The Analytical Method of Fluorescence*, Science

Publisher, Beijing, China, 1990.

- [46] I. Haq, "The thermodynamics of drug—biopolymer interaction thermodynamics of drug—DNA interactions," *Archives of Biochemistry and Biophysics*, vol. 403, pp. 1–15, 2002.
- [47] P. D. Ross and S. Subramanian, "Thermodynamics of protein association reactions: forces contributing to stability," *Biochemistry*, vol. 20, no. 11, pp. 3096–3102, 1981.
- [48] Z. Wang, Z. Zhang, D. Liu, and S. Dong, "A temperaturedependent interaction of neutral red with calf thymus DNA," *Spectrochimica Acta A*, vol. 59, no. 5, pp. 949–956, 2003.
- [49] H. Heli, S. Z. Bathaie, and M. F. Mousavi, "Electrochemical investigation of neutral red binding to DNA at the surface," *Electrochemistry Communications*, vol. 6, no. 11, pp. 1114– 1118, 2004.
- [50] J. B. Lepecq and C. Paoletti, "A fluorescent complex between ethidium bromide and nucleic acids. Physical-Chemical characterization," *Journal of Molecular Biology*, vol. 27, no. 1, pp. 87–106, 1967.
- [51] V. W. F. Burns, "Fluorescence polarization characteristics of the complexes between ethidium bromide and rRNA, tRNA, and DNA," *Archives of Biochemistry and Biophysics*, vol. 145, no. 1, pp. 248–254, 1971.
- [52] Y. Cao, Y. J. Li, and X. W. He, "Studies on Neutral Red as interacting mode spectroscopic probe of DNA," *Chemical Journal of Chinese Universities*, vol. 20, pp. 709–712, 1999.
- [53] N. Yongnian, D. Shan, and K. Serge, "Interaction between quercetin—copper(II) complex and DNA with the use of the Neutral Red dye fluorophor probe," *Analytica Chimica Acta*, vol. 584, pp. 19–27, 2007.